immune thrombocytopenia
Conditions
Interventions
Hetrombopag group:Hetrombopag(Oral)
Avatrombopag group:Avatrombopag(Oral)
Eltrombopag:Eltrombopag(Oral)
Sponsors
Fuyang People's hospital
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: (1) The diagnosis meets the criteria for primary immune thrombocytopenia in children in the 2021 version; (2) Aged 1 to 18; (3) Physical strength score meets level 1-3 (WHO standard); (4) Bone marrow cell morphology: megakaryocytes in bone marrow >=50; (5) Children with newly diagnosed ITP must have received standardized first-line treatment that is ineffective or dependent on first-line treatment. (6) After treatment, the platelet count is still = 6 months of persistent ITP or chronic ITP; (7) Family members agree and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Severe dysfunction of important organs such as heart, liver, and kidney; (2) other malignant tumors and autoimmune diseases; (3) Children with contraindications to the use of eltrombopag, hetrombopag or avatrombopag; (4) There are various situations that other researchers believe cannot be carried out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate after 8 weeks of drug treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with CR and PR after 8 weeks of drug treatment;Maximum duration and total duration of cr/pr after 24 weeks of drug treatment;Proportion of patients with at least one response within 8 weeks of drug treatment;First onset time of drug treatment;Proportion of patients requiring rescue treatment with protocol cancellation;Proportion of patients who responded after 2, 3, 4, 5, 6, 7, and 8 weeks of drug treatment; | — |
Countries
China
Contacts
Public ContactXu Zhang
Fuyang People's hospital
Outcome results
None listed